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Abstract
Background: Data on adverse drug reactions (ADRs) related to antiretroviral (ARV) use in public health practice are
few indicating the need for ART safety surveillance in clinical care.
Objectives: To evaluate the incidence, type and risk factors associated with adverse drug reactions (ADRs) among
patients on antiretroviral drugs (ARV).
Methods: Patients initiated on ARVs between May 2006 and May 2009 were evaluated in a retrospective cohort
analysis in three health facilities in Nigeria. Regimens prescribed include nucleoside backbone of zidovudine (AZT)/
lamivudine (3TC), stavudine (d4T)/3TC, or tenofovir (TDF)/3TC in combination with either nevirapine (NVP) or
efavirenz (EFV). Generalized Estimating Equation (GEE) model was used to identify risk factors associated with
occurrence of ADR.
Results: 2650 patients were followed-up for 2456 person-years and reported 114 ADRs (incidence rate = 4.6/100
person-years).There were more females 1706(64%) and 73(64%) of the ADRs were reported by women. Overall, 61
(54%) of ADRs were reported by patients on AZT with 54(47%) of these occurring in patients on AZT/NVP. The
commonest ADRs reported were pain 25(30%) and skinrash 10(18%). Most ADRs were grade 1(39%) with only 1%
being life threatening (grade 4). Adjusted GEE analysis showed that ADR was less likely to occur in patients on
longer duration of ART compared to the first six months on treatment; 6-12 months AOR 0.38(95% CI:0.16-0.91)
and 12-24 months AOR 0.34(95% CI:0.16-0.73) respectively. Compared to patients on TDF, ADR was less likely to
occur in patients on d4T and AZT AOR 0.18(95% CI 0.05-0.64) and AOR 0.24(95% CI:0.7-0.9) respectively. Age,
gender and CD4 count were not significantly associated with ADRs.
Conclusion: ADRs are more likely to occur within the first six months on treatment. Close monitoring within this
period is required to prevent occurrence of severe ADR and improve ART adherence. Further research on the
tolerability of tenofovir in this environment is recommended.
Keywords: Adverse drug reactions, ADR, Antiretroviral, Zidovudine, Stavudine, Tenofovir, HIV/AIDS, Nigeria, Inci-
dence, Risk factors
Background
The concerted efforts of developed nations and interna-
tional organizations have significantly reduced the
impact of the HIV epidemic in developing countries by
providing the means to scale up care and treatment.
Millions of eligible HIV infected patients have access to
life prolonging antiretroviral (ARV) drugs. This has led
to appreciable decrease in HIV related morbidity and
mortality [1-4]. Like most chronically administered
drugs, ARVs have documented toxicities and adverse
effects. ADRs range from mild to life threatening with
short and long term effects, however little is known
about the adverse drug reactions (ADR) of ARVs in
many HIV programs in the public health sector of
developing countries [2]. The spectrum of adverse
effects associated with ARVs may vary between devel-
oped and developing countries [5]. Variance in psycho-
logical and socioeconomic support of HIV positive
patients in the public health sector of developing
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ADRs to antiretroviral a necessity. Studies on the inci-
dence of ADR from developing and developed countries
have reported incidence of ADR among patients on
ARVs to range between 11%-35.9% [6,7] with incidence
as high as 54% [8] in the presence of opportunistic
infection. Incidence of severe ADR has been reported to
be as high as 10% [6] with a study observing an inci-
dence rate of 8 per 100 person years [4]. The long term
effects of ARTs are largely unknown but ongoing
research provides insights into some ADRs of ARV [9].
These include peripheral neuropathy and lipodystrophy
associated with stavudine,[3,4] anaemia associated with
zidovudine [10,11] and nevirapine based hepatotoxicity
and rash [12-22]. Incidence of hepatotoxicity was
observed to be 16% and 8% for patients on NVP and
EFV respectively [23] while incidence of anaemia ranged
from 3- 12% among patients on zidovudine in develop-
ing countries including Nigeria [5].
There is substantial evidence linking treatment success
to adherence to ARVs [4,15]. However adherence to
treatment is closely linked to adverse drug reactions
[4,9,15]. It is thus imperative that clinicians clearly
understand ADRs, readily recognize them in patients
and manage them effectively. Most studies on ADRs are
clinical trials and represent a select group of cohort;
however studies of large cohorts of unselected patients
a r em o r es u i t e d[ 4 ]t oi n f o r mo nt h es i t u a t i o no fA D R s
in actual clinical practice of the public health sector.
Nigerian operates a universal health care system which
supports the provision of primary, secondary and ter-
tiary levels of health services [24]. Primary health care is
funded by the local government, while secondary and
tertiary level care is funded by the state and federal gov-
ernment respectively. Delivery of healthcare is decentra-
lized to the state level, leading to much variation in
resources and funding. In 2004, Nigeria received over
$400 million dollars in funding to scale up ART and
part of this fund was implemented by Family Health
International under the Global HIV/AIDS Initiative
Nigeria (GHAIN) project. This resulted in the influx of
ART into the country on a large scale.
Admission into the GHAIN supported ART program
represents the typical approach to ART care and treat-
ment in public health setting. Typically it starts with the
HIV counselling and testing and determination of the
patients HIV status using rapid test kits. The eligibility
for ARV is established using clinical staging and CD4
count (stage I or II with CD4 count < 350 or Stage IV
irrespective of CD4 for adults; CD4 < 25% for children
less than 11 months and CD4 less than 20% for children
between the ages of 12-35 months) as per the Nigerian
national guidelines [25]. Drugs, laboratory testing and
clinical consultation are provided free of charge.
There are no known studies to the best of our knowl-
edge that provides reliable information on the adverse
drug reactions to ART in Nigeria. This study is the lar-
gest cohort study conducted in Nigeria and one of the
largest cohort studies in West Africa and thus presents
complementary information on ADRs in ART care and
treatment. The purpose of this paper was to estimate
the incidence of known ADRs and to determine risk fac-
tors associated with ADRs among HIV positive patients
on ARVs.
Methods
This study was a retrospective cohort analysis of pre-
scription events that were routinely monitored for all
patients on ART at the study sites.
Study sites
The study was conducted at three public hospitals - two
secondary level hospitals (Maitama District Hospital,
Abuja, and Calabar General Hospital, Calabar) and one
tertiary level hospital (Federal Medical Center, Owo).
Collectively, they serve over 3000 HIV/AIDS patients
with support from the Global HIV/AIDS Initiative,
Nigeria (GHAIN), a USAID funded program managed
by Family Health International (FHI). Like most public
hospitals, the three sites serve mostly uninsured popula-
tion and operate in an environment characterized by
low staff morale, shortage of staff, irregular supply of
commodities and weak management systems in general.
GHAIN’s support to the sites included infrastructure
renovations in the clinical area, laboratory and phar-
macy, laboratory equipment, training on HIV related
topics, provision of job aids, supply of drugs and
strengthening the M&E system. An electronic medical
record system, the Lafiya Management Information Sys-
tem (LAMIS) was established in these sites since 2007.
Study population and sample
The cohort included all patients who were initiated on
ART between May 2006 and May 2009 and had at least
one follow up clinical visit after commencing ARVs
between May 2009 and May 2010. Once eligible for
ARVs, all patients are initiated on combination antire-
troviral therapy consisting of a nucleoside backbone of
zidovudine (AZT)/lamivudine (3TC), stavudine (d4T)/
3TC, or tenofovir (TDF)/3TC in combination with
either nevirapine (NVP) or efavirenz (EFV). Any ARV
regimen outside these groups was classified as others.
Thereafter, the patient was reviewed monthly for two
months. At each appointment, adherence counselling
was provided. The patient was subsequently given two
monthly prescriptions if found tolerant and adherent to
the medication. Baseline CD4, haematology and chemis-
try test are conducted for all patients and follow up
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as determined by the physician. Ethical approval was
obtained from the National Health Research Ethics
Committee, Nigeria.
Data collection and management
Active ADR screening commenced in May 2009 under
the GHAIN project, however passive screening of ADR
had been ongoing and data captured on the patient’s
ART care card was designated as either yes/no, though
details of the ADR was not captured. GHAIN developed
a structured ADR screening form modified from World
Health Organization and closely related to the ADR
form used by the National Food and Drug Agency
(NAFDAC). The ADR screening form was designed to
identify 38 ADRs that occurred in different organ sys-
tems, namely skin and appendages, musculoskeletal sys-
tem, cardiovascular/respiratory system, central and
peripheral nervous system, gastrointestinal/hepato-bili-
ary/renal system, metabolic/endocrine system and sys-
temic signs/symptoms. It also allowed for grading of the
ADR reported and documents any intervention pro-
vided. ADRs were graded on a four point scale using
the W.H.O. severity grading [26]; Grade 1 was classified
as “mild” and no limitation of daily activities; Grade 2
classified as “moderate” with mild to moderate limita-
tion of activities; Grade 3 classified as “severe” with
marked limitation of activities and Grade 4 classified as
“life threatening” with extreme limitation of activities
and significant medical intervention.
Clinicians and pharmacist were trained on the content
and use of the form by the Medical Services Department
of FHI in collaboration with Howard University Conti-
nuation Education project (HUCE PACE). They were
required to use the form on all patients on ARV at
every clinical visit. Each visit screened for an ADR is
captured as a yes/no (i.e. yes if an ADR is reported) and
binary outcome of 1 was designated if the screening
yielded an ADR (i.e. value of 0 if no ADR was reported).
All ADRs reported were reviewed by a pharmacovigi-
lance committee (PVC) in each of the sites. Each site
had its own PVC which is made up of physicians, phar-
macists and laboratory scientists. This committee was
responsible for establishing causality of any ADR
reported. LAMIS generated an ADR report which pro-
vided details of current ART regimen, concomitant
medication taken by the patient and most current
laboratory parameters of each patient. This information
was evaluated per case and causality established before
the ADR report is sent to the National pharmacovigi-
lance center under the jurisdiction of the National
Agency for Food and Drug Administration and Control.
The LAMIS also captured sociodemographic informa-
tion of each patient such as age, sex and physical
address including local government area. All patients
clinical encounter (clinical visit, drug refill, laboratory
tests) including ADRs were entered into the LAMIS
database daily. Data from the LAMIS is backed up daily
and domiciled at a central server in a secure location
within the hospital. Every month, the data were
reviewed by the health facility records officer for com-
pleteness and issues identified are discussed at the
monthly Multi-LAMIS Evaluation Group (MLEG) meet-
ing. This group was a facility based health management
g r o u pt h a tw o r k e da sap r o g r a ms u p p o r tg r o u pa n d
aimed to ensure program and data ownership and
increased data use at the facility level. Members
included all cadres of health staff; clinician, pharmacist,
nurses, lab scientist, record officers e.t.c.
Toxicity definition
We used the WHO definition of ADR as any response
to a medicine which is noxious and unintended, and
which occurs at doses normally used in man [27]. ADRs
were evaluated using standard clinical signs and
symptoms.
Data availability
Each LAMIS supported site had three full time data
clerks that supported data entry at multiple service
delivery areas; general clinic, pharmacy, laboratory and
tuberculosis clinic. Patients’ data were captured daily
and when back log of data occurred, they were captured
by the end of the week.
Statistical analysis
Data from the LAMIS was exported to STATA 10 soft-
ware (Stata Corporation, College Station, Texas). Follow
up data were censored as of May 31
st 2010. Descriptive
and univariate analysis were performed on quantitative
data. Median values were used to group CD4 count.
Other risk factors include W.H.O. clinical stage, age,
sex, duration on treatment and type of regimen pre-
scribed. The Wilcoxon sign rank test was used to com-
pare changes in continuous variables while chi square
(c
2) test was used to test the statistical significance of
categorical variables by regimen group. Given the multi-
ple screening of ADR per person, generalized estimating
equation (GEE) with logit link was used to determine
risk factors associated with ADRs [28,29]. Independence
correlation structure was used to account for repeated
observations from ADR screening on the same patient
over time.
The incidence rate of ADR was expressed as the num-
ber of patients with at least one occurrence of the given
event per 100 person years [10]. Incidence rate was cal-
culated by time to event method. Patients experiencing
an ADR drug reaction were censored at the first
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ment or transferred out to another treatment facility
were also censored at time of event. Patients not experi-
encing any ADR were censored at the end of the obser-
vation period. Total time of observation contributed by
each patient was summed up to obtain total person
years of observation. A p-value < 0.05 was considered to
be significant for all test conducted.
Results
Baseline characteristics
4103 patients initiated ART between May 2006 and May
2009. 1453 were excluded from the analysis (Figure 1)
because they had no clinical visits in the observation
period. During the one year of observation period 2,650
patients had 13,479 clinical visits, an average of five vis-
its per patient. Table 1 shows the baseline characteristics
of the study population. There were more females 1706
(64%) than males 944 (36%).
The median interval between follow up visits was 2
months (IQR 1.8-2.7). About 80% of the patients were
between the ages of 15-46 years, median age was 32
years (IQR 27-40). Clinically, 725 (28%) patients were
diagnosed with Stage I disease at initiation. 2139 (81%)
patients had at least one CD4 count done during the
period under observation. The median baseline CD4
count was 172 cells/μL (IQR 85 - 275). It doubled dur-
ing follow up, to a median CD4 count of 354 cells/μL
(IQR 223 - 517) [p < 0.001].
Of the 2650 patients, 1374 (52%) were on zidovudine
based regimen, 1223 (46%) on stavudine based regimen,
46 (1.7%) on tenofovir based regimen and 7 (< 1%) on
other regimen. Of the 13, 479 clinical visits, 10,084
(75%) were screened for an ADR and 114 (1.13%) visits
reported an ADR.
Distribution of ADRs
Table 2 shows onset of ADR and distribution by specific
characteristics. Of the 114 ADRs reported 83 (73%) had
their specific detail collected and 15 patients (28%)
reported at least 2 ADRs. Forty-six (45%) of the 114
reported ADRs occurred between 12-24 months on
treatment. Sixty-one ADRs (54%) occurred with patients
on zidovudine based regimen, 50(44%) with patients on
stavudine based regimen and 3 (3%) with patients on
tenofovir based regimen.
The ADR screening program implemented by the
GHAIN project routinely screened 38 adverse drug
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Figure 1 Distribution of patients by regimen and ADR.
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severity of ADRs, most of the ADRs reported were
Grade 1 (39%), Grade 2 and 3 ADRs were 32% and 28%
respectively, while 1% of ADRs was found to be life
threatening. Amongst those that reported an ADR, no
change in regimen was documented.
Incidence of ADRs
Patients were followed up for a total of 2456 person-
years yielding an incidence rate (IR) of 4.6/100 person-
years. Overall incidence of ADR by nucleoside backbone
was 4.4%, 4.1% and 6.5% for patients on AZT, d4T and
TDF based regimen respectively while by non-nucleo-
side base, incidence was 4.2% and 4.9% for patients on
nevirapine and efavirenz respectively.
Table 3 shows the incidence rates of reported ADR by
regimen group. Pain/tingling/numbness was the most
common ADR reported (30%) with an IR of 2.1 and 0.1
per 100 person-years among patients on d4T and AZT
based regimen respectively, followed by skin rash (18%)
with an IR of 2.6, 0.5 and 0.6 per 100 person years
among patients on TDF, d4T and AZT respectively.
Risk factors for ADR
Table 4 shows risk factors associated with ADRs. The
adjusted GEE analysis showed that patients on longer
duration of treatment had decreased odds of developing
an ADR compared to patients in their first six months
on treatment, 6-12 months (AOR 0.38, 95% CI 0.16-
0.91, P=0.03), 12-24 months (AOR 0.35, 95% CI 0.16-
0.73, P = 0.005), 24-36 months (AOR 0.37, 95% CI 0.14-
0.96, P=0.05). With TDF based regimen as the refer-
ence, patients on d4T (AOR 0.18, CI 0.05-0.64, p =
0.009) and AZT (AOR 0.24, CI 0.07-0.904, p = 0.034)
were less likely to report an ADR. Age (AOR 1.27, CI
0.59-2.77, p = 0.544) gender (AOR 0.83, 0.43-1.57, p =
0.562) and CD4 count (AOR 0.93, CI 0.51-1.70, p =
0.816) were not significantly associated with developing
an ADR.
Discussion
The likelihood of developing an adverse drug reaction
was highest in the first six months of commencing anti-
retroviral therapy. Xavier et al. [4] proffered an explana-
tion that early occurrence of ADRs is an expression of a
mechanism of intrinsic intolerance rather than of a
time-dependent toxic accumulation process. Close mon-
itoring of patients within this time frame is thus impera-
tive to prevent the occurrence of severe ADRs, improve
adherence as well as improve documentation of ADRs.
However 45% of the reported ADRs occurred within 12-
24 months of commencing ARVs. This calls for the
need to intensify long term ADR monitoring in patients
on ARV. Some studies have proposed time-dependent
Table 1 Baseline Characteristics of Study Population
Variable % (n)
Sex
Female 64.38 (1,706)
Male 35.62 (944)
Age (years)
< 15 6.26 (144)
16-45 80.0 (2120)
> 45 13.74 (364)
Baseline CD4
< = 200 58.72 (1556)
200 - 350 26.68 (707)
> 350 14.60 (387)
Median baseline CD4 (IQR) 172 (85-275)
Baseline WHO Staging*
Stage I 27.36 (725)
Stage II 26.60 (705)
Stage III 40.23 (1066)
Stage IV 4.08 (108)
ART Regimen
NRTI Backbone
Zidovudine based 51.85 (1374)
Stavudine based 46.15 (1223)
Tenofovir based 1.74 (46)
Others 0.26 (7)
NNRTI Backbone
Nevirapine_based 80.04 (2121)
Efavirenze_based 19.96 (529)
* Total do not add up to 114 due to missing data
Table 2 Onset and Distribution of ADR
Onset of Adverse Drug Reaction From ART Initiation* (n = 102)
Onset of ADR n (%)
0-3 months 8 (7.84)
3-6 months 14 (13.73)
6-12 months 22 (21.57)
12-24 months 46 (45.10)
24-36 months 10 (9.80)
> 36 months 2 (1.96)
ADR distribution by age (n = 114)
< 15 years 0
16-45 years 97 (85.09)
> 45 years 17 (14.91)
ADR distribution by gender (n = 114)
Male 41 (35.96)
Female 73 (64.04)
* Total do not add up to 114 due to missing data
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Specific ADR by Organ System AZT_based (n) d4T_based (n) TDF_based (n) Total (%)
Gastrointestinal
Abdominal pain - 0.09 (1) - 1 (1.20)
Diarrhea 0.32 (4) - - 4 (4.82)
Dyspepsia 0.08 (1) - - 1 (1.20)
Nausea & Vomiting 0.24 (3) - - 3 (3.61)
Cardiovascular/Respiratory System
Chest pain - 0.09 (1) - 1 (1.20)
Cough - 0.09 (1) - 1 (1.20)
Skin and Appendages
Pruritus 0.24 (3) 0.61 (7) - 10 (12.05)
Steven Johnson syndrome 0.08 (1) - - 1 (1.20)
Skin rash 0.64 (8) 0.52 (6) 2.56 (1) 15 (18.07)
Central and Peripheral Nervous System
Headache 0.08 (1) 0.09 (1) - 2 (2.41)
Dizziness 0.08 (1) 0.44 (5) - 6 (7.23)
Insomnia 0.16 (2) - - 2 (2.41)
Nightmare 0.08 (1) 0.09 (1) - 2 (2.41)
Pain/Tingling/Numbness 0.08 (1) 2.09 (24) - 25 (30.12)
Musculoskeletal System
Myalgia 0.08 (1) - - 1 (1.20)
Systemic Signs/Symptoms
Rigor 0.08 (1) - - 1 (1.20)
Fatigue 0.08 (1) - - 1 (1.20)
Fever 0.08 (1) - - 1 (1.20)
Total 34 48 1 83
Table 4 Generalized Estimating Equation Analysis for Risk Factors Associated with ADR
Variables N (%) Unadjusted OR p Adjusted OR p
Gender
Female 1706 (64.4)
Male 944 (35.6) 1.11(0.71-1.73) 0.663 0.83 (0.43-1.57) 0.562
Age (years)
15-45 2120 (85.3)
> 45 364 (14.7) 0.81(0.48-1.36) 0.422 1.27 (0.59-2.77) 0.544
Regimen
TDF_based 46 (1.7)
AZT_based 1374 (52.0) 0.56 (0.18-1.75) 0.319 0.24 (0.07-0.90) 0.034
D4T_based 1223 (46.3) 0.33 (0.10-1.03) 0.057 0.18 (0.05-0.64) 0.009
Duration on treatment (months)
0-6 21 (0.79)
6-12 79 (2.98) 0.54 (0.33-0.89) 0.02 0.38 (0.16-0.91) 0.03
12-24 259 (47.5) 0.25 (0.15-0.41) < 0.001 0.35 (0.16-0.73) 0.005
24-36 952 (35.9) 0.16 (0.08-0.34) < 0.001 0.37 (0.14-0.96) 0.042
CD4 cell count cells/μL
< 350 950 (44.8)
> 350 1180 (55.2) 1.08 (0.6-2.0) 0.791 0.93 (0.51-1.70) 0.816
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ADR long after commencing medication. Thus monitor-
ing for ADR should be an ongoing process as we have
both early onset and late onset ADRs. Adding a labora-
tory component to the ADR screening would go a long
way in determining biochemical markers that would
help to improve patient management. However from a
programmatic aspect in a resource constrained environ-
ment, having sound knowledge of the risk factors or
common ADRs associated with different ARV regime
can help focus scarce resources to managing ADRs in
these settings.
Since adverse drug reactions are the single most com-
mon reason for poor adherence to treatment, identifying
risk factors for the occurrence of ADRs is of crucial
importance to optimize the initial choice of ARVs regi-
men before initiating therapy and to adapt the pace of
surveillance to each unique situation [4]. Our study
showed no difference in reported ADR between men
and women, however Bonfati et al [7]. observed that
women experienced significantly greater number of
adverse effects compared to men. Though the popula-
tion of patients on tenofovir based regimen was small
compared to AZT and d4T, our data shows that
patients on AZT or d4T were less likely to report an
ADR than those on TDF. A multisite trial in Africa,
found tenofovir therapy to be associated with 1.3% rate
of significant nephrotoxicity which was comparable to
other regimen,[5,30] thus showing no significant toxicity
difference between tenofovir and other regimens. This
raises a sentinel sign that perhaps drug response to TDF
in this setting is not in conformity with the results from
other studies where drug profile of TDF has been super-
ior over AZT and d4T. A closer look at the drug profile
and toxicity of TDF is urgently needed to better under-
stand its tolerance in patients in this setting. Further-
more, the most common side effect of tenofovir is renal
impairment as measured by reduced creatinine clear-
ance,[31] thus as tenofovir replaces d4T as the nucleo-
side backbone of choice in HIV treatment, laboratories
in resource poor settings must be strengthened to able
to conduct this test.
Incidence of anaemia was low at 4% and occurred
exclusively in patients on AZT. This is similar to other
studies conducted in Nigeria, Coˆ te d’Ivoire, Haiti and
India that observed anaemic rates of 3%-12% [5,32-38].
The incidence of skin toxicity (18%) is similar to that in
other reports,[15,17] though some reports have observed
low incidence of skin toxicity,[10,31] however the inci-
dence of Steven-Johnson syndrome (1%) was similar to
other reports which reported less than 5% [14-17]. Most
of the reported ADRs (71%) were mild to moderate and
self limiting in nature while 1% were life threatening.
This suggests good tolerance level to ARVs in general.
W h i l eo t h e rs t u d i e sh a v ea ssociated low CD4 count at
treatment initiation as a risk factor for ADR [5], our
study did not show any association between CD4 cell
count and clinical stage with ADRs.
Our study takes strength in its large sample size. This
is the largest cohort of patients who have been surveyed
in Nigeria for ADR using active surveillance. It also pre-
sents ADR outcomes in a large public health program
and more closely presents treatment outcomes that are
more generalizable than clinical studies. Finally data in
this study was of good quality giving the scale of the
program and its routine nature of collection. Mathieu
Forster et al. [39] assessed data quality for ART services
in low income countries by evaluating the availability of
six key variables (age, sex, W.H.O clinical staging at
baseline and follow-up, CD4 count and year of ART
initiation) and calculating the proportion of missing
data to determine the quality of data and the median
was found to be 10.9%. The median of the percentages
of missing variables was 0% for all sites surveyed.
This study has some limitations. The study included
patients who had initiated ART before active surveil-
lance of ADR commenced. Though this provided infor-
mation on long term adverse effects, we may have
missed early onset ADR from these patients. The small
sample size of patients on tenofovir based regimen lim-
its our ability to compare ADR reported by this group
with other regimen groups. Also the ADR screening
tool was structured and thus, does not allow details of
unknown ADR to be captured and graded, thus the
study was confined to report on known ADRs only.
Finally, not all ADRs reported had their complete details
collected and graded. Thus the specific ADRs in this
study are most likely under reported.
Conclusion
Incidence rate (4.6/100 person years) of ADRs is low
amongst patients on ARVs. Active screening of ADRs
has increased the documentation of the occurrence of
these events and should be scaled up to all facilities pro-
viding comprehensive care to HIV patients. Improving
quality of care to patients by providing ADR screening
provides an avenue for early identification and subse-
quently treatment of adverse drug reactions. Further
evaluation of patients on tenofovir would be beneficial
in documenting adverse drug reactions related to teno-
fovir as well as its tolerability. Finally more field based
studies in resource constrained settings should be con-
ducted and ADRs related to ARVs evaluated and com-
pared to ADRs observed from clinical trials. This will
provide valuable insight in the incidence, prevalence and
type of ADRs associated with ARVs.
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